BRPI0519355A2 - compostos para tratamento contra flaviviridae - Google Patents

compostos para tratamento contra flaviviridae

Info

Publication number
BRPI0519355A2
BRPI0519355A2 BRPI0519355-9A BRPI0519355A BRPI0519355A2 BR PI0519355 A2 BRPI0519355 A2 BR PI0519355A2 BR PI0519355 A BRPI0519355 A BR PI0519355A BR PI0519355 A2 BRPI0519355 A2 BR PI0519355A2
Authority
BR
Brazil
Prior art keywords
flaviviridae
compounds
treatment against
against flaviviridae
preventing
Prior art date
Application number
BRPI0519355-9A
Other languages
English (en)
Inventor
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0519355A2 publication Critical patent/BRPI0519355A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTOS PARA TRATAMENTO CONTRA FLAVIVIRIDAE. São reveladas ciclosporinas de ligação de ciclofilina não imu- nossupressivas, por exemplo, de fórmula I, Ia ou II conforme definido aqui, neste requerimento de patente, tendo propriedades úteis na prevenção ou tratamento de infecções por Flaviviridae e doenças induzidas por Flaviviridae.
BRPI0519355-9A 2004-12-23 2005-12-20 compostos para tratamento contra flaviviridae BRPI0519355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867604P 2004-12-23 2004-12-23
PCT/US2005/046058 WO2006071618A1 (en) 2004-12-23 2005-12-20 Compounds for flaviviridae treatment

Publications (1)

Publication Number Publication Date
BRPI0519355A2 true BRPI0519355A2 (pt) 2009-01-20

Family

ID=36218613

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519355-9A BRPI0519355A2 (pt) 2004-12-23 2005-12-20 compostos para tratamento contra flaviviridae

Country Status (17)

Country Link
US (1) US20090214464A1 (pt)
EP (1) EP1830870A1 (pt)
JP (1) JP2008525458A (pt)
KR (1) KR20070089954A (pt)
CN (1) CN101084005A (pt)
AU (1) AU2005322241B2 (pt)
BR (1) BRPI0519355A2 (pt)
CA (1) CA2587586A1 (pt)
IL (1) IL183780A0 (pt)
MA (1) MA29097B1 (pt)
MX (1) MX2007007721A (pt)
NO (1) NO20073765L (pt)
NZ (1) NZ555142A (pt)
RU (1) RU2007128098A (pt)
TN (1) TNSN07240A1 (pt)
WO (1) WO2006071618A1 (pt)
ZA (1) ZA200703907B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004222306A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
WO2006039163A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技（武汉）有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US20040033946A1 (en) * 2000-10-19 2004-02-19 Futoshi Shibasaki Cell damage inhibitor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
PT1793844E (pt) * 2004-10-01 2011-03-10 Debiopharm Sa Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c
US7897565B2 (en) * 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
MA29097B1 (fr) 2007-12-03
KR20070089954A (ko) 2007-09-04
AU2005322241A1 (en) 2006-07-06
CA2587586A1 (en) 2006-07-06
US20090214464A1 (en) 2009-08-27
ZA200703907B (en) 2009-08-26
MX2007007721A (es) 2007-08-14
NZ555142A (en) 2010-03-26
TNSN07240A1 (en) 2008-11-21
IL183780A0 (en) 2007-09-20
AU2005322241B2 (en) 2010-02-18
JP2008525458A (ja) 2008-07-17
WO2006071618A1 (en) 2006-07-06
EP1830870A1 (en) 2007-09-12
NO20073765L (no) 2007-09-19
RU2007128098A (ru) 2009-01-27
CN101084005A (zh) 2007-12-05

Similar Documents

Publication Publication Date Title
NO20073765L (no) Forbindelser for behandling av flaviviridae
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MY145721A (en) Non-irritating compositions containing zinc salts
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK1419154T3 (da) Rapamycin-29-enoler
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
NO20070726L (no) Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
EA201000329A1 (ru) Циклические депсипептиды
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
EA200970338A2 (ru) Агонисты рецептора еро человека, композиции, способы и применение для предотвращения или лечения состояний, связанных с интолерантностью к глюкозе

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.